InvestorsHub Logo
Followers 6
Posts 2155
Boards Moderated 0
Alias Born 11/26/2014

Re: Tekterra post# 26331

Monday, 04/24/2017 11:54:05 AM

Monday, April 24, 2017 11:54:05 AM

Post# of 38634
Tek- Does Seroquel approval and commercialization solve the cash problem? I think so... There may be a little gap until they get the first check but I am pretty confident they will be getting about $1M or a little more in Seroquel revenues per month. With Seroquel at $3M per quarter and Focalin at $1.5M per quarter we have $4.5M per quarter. Current burn rate is $3.25-3.5M per quarter. There might be a month or two until checks start rolling in that they are very tight. The ATM might be able to be the stop gap for that period. I guess we will have to wait and see. Everyone should research P/E. The standard P/E for IPCI sector is 50-60. The forward P/E for IPCI sector is 20-30. Should be an interesting year. Especially if Pristiq and/or Lamictal get approved. I think soon the cash flow problem will be behind IPCI. When no risk of dilution, what will bears complain about? I am sure the same old same old like management, transparency and especially the Purdue lawsuit. The big complaint will be that the future of Rexista is in jeopardy because of lawsuit...
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPCI News